ABUS

Arbutus Biopharma Corporation (ABUS) 10Y Growth Potential Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Growth Runway

ABUS has a large cash balance and minimal debt, giving it flexibility to fund development and operations.

Revenue base remains small relative to market cap, so long-term upside still depends on sustained commercialization and pipeline execution.

No material change this month.

Profitability

Margins are exceptionally strong, with gross margin near 100% and operating margin above 80%.

Return on equity and return on invested capital remain very high, indicating efficient capital use.

No material change this month.

Financial Strength

The balance sheet is extremely liquid, with a current ratio above 80x and cash ratio above 5x.

Debt is effectively negligible, and solvency metrics remain very strong.

No material change this month.

Valuation

The stock trades at a premium sales multiple, which still requires continued growth and execution to justify.

Profitability supports a reasonable earnings multiple, but negative free cash flow keeps valuation less compelling on cash-based measures.

No material change this month.

Execution Risk

Cash flow remains negative despite strong accounting earnings, which creates a disconnect investors need to monitor.

Working-capital metrics are unusually distorted, suggesting the business may still have timing or collection risks.

No material change this month.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Arbutus Biopharma Corporation. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →